Skip to main content

Roche and ETH training the next generation of researchers

| News

Roche and ETH training the next generation of researchers


Roche, the Basel-based life sciences firm, and the Swiss Federal Institute of Technology in Zurich (ETH) are joining forces to train biomedical researchers. At the ETH Zurich location in Basel, new drug development methods are also being researched.


Roche and the Swiss Federal Institute of Technology in Zurich (ETH) have agreed a research and training cooperation, further details of which can be found in a press release. This partnership will primarily be focused on the Department of Biosystems Science and Engineering (D-BSSE) of ETH Zurich, which is based in Basel. Moreover, the Basel-based life sciences firm’s new Institute of Human Biology (IHB) as well as its Pharma Research and Early Development department are located there too. “This kind of collaboration between academia and industry is unique”, as Vanessa Wood, Vice President Knowledge Transfer and Corporate Relations at ETH Zurich, explains in the press release.

Attract the best researchers

The cooperation is being implemented across two separate programs, one of which is focused on new methods of bioengineering and other on cellular and genetic model systems. A total of 20 doctoral students and 20 postdoctoral fellows, fully funded by Roche, will collaborate with researchers from Roche and ETH Zurich across a period of three to four years. “We are convinced that through our partnership and collaboration, we will attract and work with some of the best researchers in the world”, comments Hans Clevers, Head of Pharma Research and Early Development at Roche, in the press release. Through this joint work, Roche and ETH Zurich will therefore be training the next generation of biomedical researchers, who will become specialists to deal with future challenges.

In addition, the cooperation between Roche and ETH also provides a platform to research methods for the development of new drugs. For example, the researchers can work with organoids, 3D models of human organs. However, they will also gain experience in the area of machine learning algorithms for the evaluation of huge volumes of data. “Our new strong partnership with Roche empowers future leaders in bioengineering and translational medicine”, comments Professor Daniel Müller, who heads up the D-BSSE, in the press release.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.